Fig. 2 Risk of bias summary for included studies.
Note: A ”+” stands for low risk, ”−” for high risk, and ”?” for unclear risk.
Figure 3, including four articles, shows a forest plot of the risk ratio of patients whose MRS score was 0-1 at day 90 between fingolimod plus standardized treatment and standardized treatment alone. This finding suggested that the risk ratio of the proportion of patients whose MRS score was 0-1 at day 90 between fingolimod plus standardized treatment and standardized treatment alone was 2.59 (95%CI, 1.48 to 4.56). A random-effect model was used. Sensitivity analyses were performed by removing each study in turn and re-analyzed it. No studies were found to significantly affect heterogeneity.